(Q81793757)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

title

Immunogenicity of an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine in 2-year old children (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

main subject

Neisseria meningitidis

1 reference

1

Dan M Granoff

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Amy Morgan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Jo Anne Welsch

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

publication date

1 July 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

4307-4314

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

The future of meningococcal vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Protective activity of group C anticapsular antibodies elicited in two-year-olds by an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Naturally-acquired immunity to Neisseria meningitidis group A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Serum group a anticapsular antibodies in a Sudanese population immunized with meningococcal polysaccharide vaccine during a group A epidemic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Human immunity to the meningococcus. I. The role of humoral antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Scientific challenges for the quality control and production of group C meningococcal conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Importance of complement source in measuring meningococcal bactericidal titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

The Changing Epidemiology of Meningococcal Disease in the United States, 1992–1996

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

inferred from DOI database lookup

7 January 2021

based on heuristic

Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Cross-Antigenicity and Immunogenicity between Capsular Polysaccharides of Group C Neisseria meningitidis and of Escherichia coli K92

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Neisseria lactamica protects against experimental meningococcal infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Development of natural immunity to Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Imperfect memory and the development of Haemophilus influenzae type B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Meningococcal serogroup a avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Meningococcal polysaccharide-protein conjugate vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.03.031

10.1016/J.VACCINE.2005.03.031

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15921829%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference